Inhibitors of the PI3K pathway have already made significant contributions to GIST, with the dual PI3K/mTOR inhibitor voxtalisib, the pan-PI3K inhibitor pilaralisib, and the PI3K-restricted inhibitor alpelisib all reducing GIST cell proliferation [164]. Here, MTOR is linked to gastrointestinal stromal tumor.